[Hybrid recombinant proteins: structure, properties and use].
The paper deals with the problem pertaining to immunotoxins which consist of two components, namely: catalytic (effector) and receptor-binding (ligand) ones. The immunotoxins are promising pharmaceutical drugs of a new generation, which are successfully used in clinical practice to treat tumor diseases, allergy, AIDS, and to transplant organs and tissues. Immunotoxins for the therapy of diabetes, autoimmune diseases, and bacterial, viral, and parasitic infections are being developed.
Urakov
N N
NN
Veriasova
G V
GV
Sokov
B N
BN
Kavyzina
L I
LI
Sergeeva
N L
NL
D000939:Epitopes; D006801:Humans; D007124:Immunoenzyme Techniques; D000922:Immunotoxins / Q000627:therapeutic use; D007239:Infections / Q000276:immunology / Q000628:therapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D014180:Transplantation
D000939:Epitopes; D000922:Immunotoxins; D011994:Recombinant Proteins